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Abstract
Introduction We conducted the present study to investigate the
potential beneficial and adverse effects of continuous positive
airway pressure (CPAP) compared with bi-level positive airway
pressure (BiPAP) noninvasive ventilation in patients with
cardiogenic pulmonary oedema.
Method We included randomized controlled studies comparing
CPAP and BiPAP treatment in patients with cardiogenic
pulmonary oedema from the Cochrane Controlled Trials
Register (2005 issue 3), and EMBASE and MEDLINE
databases (1966 to 1 December 2005), without language
restriction. Two reviewers reviewed the quality of the studies
and independently performed data extraction.
Results Seven randomized controlled studies, including a total
of 290 patients with cardiogenic pulmonary oedema, were
considered. The hospital mortality (relative risk [RR] 0.76, 95%
confidence interval [CI] 0.32–1.78; P = 0.52; I2 = 0%) and risk
for requiring invasive ventilation (RR 0.80, 95% CI 0.33–1.94; P
= 0.62; I2  = 0%) were not significantly different between
patients treated with CPAP and those treated with BiPAP.
Stratifying studies that used either fixed or titrated pressure
during BiPAP treatment and studies involving patients with or
without hypercapnia did not change the results. The duration of
noninvasive ventilation required until the pulmonary oedema
resolved (weighted mean difference [WMD] in hours = 3.65,
95% CI -12.12 to +19.43; P = 0.65, I2 = 0%) and length of
hospital stay (WMD in days = -0.04, 95% CI -2.57 to +2.48; P
= 0.97, I2 = 0%) were also not significantly different between
the two groups. Based on the limited data available, there was
an insignificant trend toward an increase in new onset acute
myocardial infarction in patients treated with BiPAP (RR 2.10,
95% CI 0.91–4.84; P = 0.08; I2 = 25.3%).
Conclusion BiPAP does not offer any significant clinical
benefits over CPAP in patients with acute cardiogenic
pulmonary oedema. Until a large randomized controlled trial
shows significant clinical benefit and cost-effectiveness of
BiPAP versus CPAP in patients with acute cardiogenic
pulmonary oedema, the choice of modality will depend mainly on
the equipment available.
Introduction
Acute cardiogenic pulmonary oedema is a common medical
emergency. The majority of patients with acute pulmonary
oedema will improve with oxygen and pharmacological ther-
apy. However, assisted ventilation may be needed in patients
with severe cardiogenic pulmonary oedema who remain
hypoxaemic and in respiratory distress despite conventional
medical therapy [1].
Studies have shown that noninvasive continuous positive air-
way pressure (CPAP) ventilation can improve gas exchange,
decrease respiratory and heart rate, reduce the need for inva-
sive ventilation [2-4] and reduce hospital mortality [5]. Nonin-
vasive bi-level positive airway pressure (BiPAP) ventilation
delivers positive airway pressure at two different levels during
inspiration and expiration, and can decrease inspiratory work
of breathing more than CPAP can alone [6]. Studies evaluat-
ing BiPAP in acute cardiogenic pulmonary oedema have
BiPAP = bi-level positive airway pressure; CI = confidence interval; CPAP = continuous positive airway pressure; RR = relative risk; WMD = weighted 
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shown that it improves gas exchange [7] and reduces the
need for invasive ventilation in patients with hypercapnic res-
piratory failure compared with conventional medical therapy
[8]. However, none of these studies demonstrated a reduction
in hospital mortality [5]. Furthermore, the results of one of the
earlier studies suggested that BiPAP compared with CPAP
might increase the risk for new onset acute myocardial infarc-
tion in patients with acute cardiogenic pulmonary oedema [9].
Whether BiPAP is advantageous compared with CPAP in
acute cardiogenic pulmonary oedema remains uncertain.
In the present meta-analysis we assessed the potential bene-
ficial and harmful effects of BiPAP compared with CPAP in
patients with acute cardiogenic pulmonary oedema. We also
assessed whether the BiPAP may be more advantageous
when the pressure used during BiPAP is titrated according to
clinical need and in the subgroup of patients with significant
hypercapnia (mean arterial carbon dioxide tension [PaCO2] >
45 mmHg).
Materials and methods
A literature search was conducted using the Cochrane Con-
trolled Trials Register (2005 issue 3), and EMBASE and
MEDLINE databases (1966 to 1 December 2005). Only ran-
domized controlled clinical trials comparing BiPAP with CPAP
in patients with acute cardiogenic pulmonary oedema were
included. Studies comparing BiPAP with CPAP in a heteroge-
neous group of patients with different causes of acute respira-
tory failure were excluded unless outcomes data for the
subgroup of patients with acute cardiogenic pulmonary
oedema were available. Studies using both CPAP and BiPAP
in the same group of patients in a crossover design were
excluded because the clinical outcomes as a result of a partic-
ular treatment modality could not be ascertained. During the
electronic database search, the following exploded MeSH
terms were used: 'bilevel', 'pressure support', 'non-invasive',
'CPAP', or 'positive pressure', with 'ventilation' or 'support' and
with 'pulmonary oedema', 'cardiac failure', 'heart failure', or
'respiratory failure'. The reference lists of related reviews and
original articles identified were searched for relevant trials.
Finally, the websites of the International Network of Agencies
of Health Technology Assessment and International Society of
Technology Assessment in Health Care were searched to
ensure that all suitable studies were included. The authors of
one study were contacted to obtain additional information but
they did not respond to the request. No studies published in
languages other than English were found in the literature
search.
Two independent reviewers examined the titles and the
abstracts of all identified trials to confirm that they fulfilled the
inclusion criteria. The same reviewers examined and recorded
the trial characteristics and outcomes independently, using a
pre-designed data abstraction form. This abstraction form was
Figure 1
Flow chart: study inclusion and exclusion in the meta-analysis Flow chart: study inclusion and exclusion in the meta-analysis. BiPAP, bi-level positive airway pressure; CPAP, continuous positive airway pressure.Available online http://ccforum.com/content/10/2/R49
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used to record information regarding the quality of the trial,
such as allocation concealment, randomization method, blind-
ing of treatment, and inclusion and exclusion criteria. The qual-
ity of the study was scored according to the Jadad scale
(range from 0 to 5, with higher scores indicating better quality)
[10], but the individual component that constitutes the quality
of the study was also described. The grading of allocation con-
cealment was based on the Cochrane approach (i.e. adequate
or uncertain or clearly inadequate). Blinding of the attending
physician who decided when to initiate invasive ventilation or
to cease noninvasive ventilation with the assigned mode of
noninvasive ventilation (for instance CPAP or BiPAP) was
required for a study to qualify as double blind. Any disagree-
ments between the two independent reviewers were resolved
by consensus. Data were checked and entered into the
Review Manager (version 4.2.6 for Windows, 2003; The
Cochrane Collaboration, Oxford, UK) database for further
analysis.
The hospital mortality and the proportion of patients requiring
invasive ventilation (or intubation) were chosen as main out-
comes of this meta-analysis because they are the most rele-
vant clinical outcomes of noninvasive ventilation in patients
with acute cardiogenic pulmonary oedema. The criteria for
requiring invasive ventilation varied between studies, but the
common criteria included poor state of consciousness (Glas-
gow Coma Scale score ≤ 13), respiratory arrest or significant
respiratory distress (respiratory rate >40 breaths/minute), per-
sistent hypoxaemia despite supplementary oxygen (arterial
oxygen tension <60 mmHg) and progressive increases in
PaCO2 despite CPAP or BiPAP treatment (>5 mmHg). The
other outcomes assessed in the meta-analysis included the
proportion of patients who developed new onset acute myo-
cardial infarction after initiation of BiPAP or CPAP, duration of
noninvasive ventilation needed till the pulmonary oedema
resolved, and length of hospital stay. The criteria and process
of weaning from CPAP or BiPAP varied between studies, but
the common criteria included absence of respiratory distress
with respiratory rate below 25 breaths/minute and pulse oxi-
metry saturation of 95% or greater. The weaning process usu-
ally involved stepwise reduction in inspiratory and expiratory
pressures (2 cmH2O) and inspired oxygen concentration
(10%).
Statistical analyses
The differences in categorical outcomes between the treat-
ment and placebo group were reported as relative risk (RR)
with 95% confidence interval (CI), using a random effect
model. The effects of CPAP or BiPAP on the hospital mortality
and the need for invasive ventilation were further stratified into
studies using either a fixed level or variable levels of airway
pressure during BiPAP treatment, and this interaction was
tested by relative risk ratio [11]. The differences in the duration
of noninvasive ventilation required until the pulmonary oedema
resolved and the length of hospital stay were reported as
weighted mean differences (WMDs), using a random effect
model. The presence of heterogeneity between trials was
assessed using the χ2 statistics and the extent of inconsist-
ency was assessed using I2 statistics [12]. Because hyper-
capnia is a predictor of requiring intubation in patients with
cardiogenic pulmonary oedema [13], sensitivity analysis was
conducted to include studies that involved patients with hyper-
capnia (mean PaCO2 > 45 mmHg) before initiation of either
CPAP or BiPAP. Publication bias was assessed by funnel plot
using hospital mortality as an end-point.
Results
We identified 17 potentially eligible studies, of which seven
studies [9,14-19], including a total of 290 patients, fulfilled the
inclusion criteria and were subjected to meta-analysis (Figure
1). Two studies used fixed level of CPAP (10 cmH2O) and
BiPAP (15 and 5 cmH2O), two studies used a fixed level of
CPAP (10 cmH2O) but titrated the level of peak inspiratory
pressure in the BiPAP group (from 15 cmH2O to achieve a
Figure 2
Forest plot: effect of BiPAP and CPAP on hospital mortality Forest plot: effect of BiPAP and CPAP on hospital mortality. BiPAP, bi-level positive airway pressure; CI, confidence interval; CPAP, continuous pos-
itive airway pressure; RR, relative risk.C
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Table 1
Characteristics of the included studies
Reference Definition of failed noninvasive 
ventilation
Participants Interventions Outcomes Factors pertaining to the quality of 
studies
[15] GCS score ≤13, persistent severe 
respiratory distress, Po2 <60 mmHg 
despite oxygen supplementation, an 
increase in PaCO2 >5 mmHg
56 patients (recruited between 
January 1999 and August 2000), 
mean APACHE II score 19.5, mean 
age 64 years, mean PaCO2 at 
presentation 40 mmHg
Variable CPAP (10–16 cmH2O), 
variable BiPAP (starting from 15 
and 10 cmH2O; maximum not 
described)
Proportion of patients with hospital 
mortality and requiring intubation, 
the duration of noninvasive 
ventilation needed and hospital 
length of stay
Allocation concealment adequate; 
study not blinded; 3.6% of patients 
did not have pulmonary oedema 
were excluded from analysis; 
analysis was by intention to treat; 
Jadad scale score 3
[9] Severe respiratory distress, inability to 
tolerate or synchronize with the 
mask, further deterioration in vital 
signs or significant haemodynamic 
compromise, Po2 <60 mmHg 
despite oxygen supplementation, an 
increase in PaCO2 >5 mmHg
36 patients, mean APACHE II score 
18, mean age 77 years, mean 
PaCO2 at presentation 50 mmHg
Fixed CPAP (10 cmH2O), fixed BiPAP 
(15 and 5 cmH2O)
Proportion of patients with hospital 
mortality and requiring intubation, 
new onset acute myocardial 
infarction, duration of noninvasive 
ventilation needed and hospital 
length of stay
Allocation concealment not clear; 
double blinding; 22% of enrolled 
patients did not have pulmonary 
oedema and were excluded from 
analysis, and 2.8% were excluded 
because of delay in starting CPAP; 
analysis was not by intention to 
treat; Jadad scale score 5
[14] Intubation determined by the 
attending physician but criteria were 
not described
16 patients (recruited between May 
and October 1997), mean APACHE 
II score not available, mean age 69 
years, mean PaCO2 at presentation 
40 mmHg
Variable CPAP (5–12.5 cmH2O), 
variable BiPAP (starting from 8 and 
3 cmH2O; maximum not described)
Proportion of patients with hospital 
mortality and requiring intubation, 
duration of noninvasive ventilation 
needed
Allocation concealment not clear; not 
blinded; no loss to follow up; 
analysis by intention to treat; Jadad 
scale score 2
[16] Respiratory arrest, respiratory pauses 
with loss of consciousness, 
agitation making nursing care 
impossible and requiring sedation, 
haemodynamic instability with 
systolic blood pressure <70 mmHg, 
and the clinician could elect to 
intubate if they felt that the patient's 
condition was not improving 
satisfactorily
71 patients, mean APACHE II score 
not available, mean age 74 years, 
mean PaCO2 at presentation not 
available
Variable CPAP (5–20 cmH2O), 
variable BiPAP (starting from 10 
and 5 cmH2O; maximum 20 and 5)
Proportion of patients with hospital 
mortality and requiring intubation, 
the duration of noninvasive 
ventilation needed and hospital 
length of stay
Allocation concealment not clear; not 
blinded; no loss to follow up; 
analysis by intention to treat; Jadad 
scale score 2
[18] Respiratory arrest, respiratory pauses 
with loss of consciousness, 
agitation making nursing care 
impossible and requiring sedation, 
haemodynamic instability with 
systolic blood pressure <70 mmHg
46 patients (recruited between March 
2002 and March 2003), mean 
APACHE II score 18, mean age 77 
years, mean PaCO2 at presentation 
54 mmHg
Fixed CPAP (10 cmH2O), variable 
BiPAP (starting with 15 and 5 
cmH2O; titration of inspiratory 
pressure to achieve tidal volume 
>400 ml)
Proportion of patients with hospital 
mortality and requiring intubation, 
new onset acute myocardial 
infarction, duration of noninvasive 
ventilation needed
Allocation concealment adequate; not 
blinded; no loss to follow up; 
analysis by intention to treat; Jadad 
scale score 3
[17] Respiratory arrest, respiratory 
pauses with loss of 
consciousness, agitation 
making nursing care impossible 
and requiring sedation, 
haemodynamic instability with 
systolic blood pressure <70 
mmHg
36 patients (recruited between 
January 2001 and January 
2002), mean APACHE II score 
18, mean age 77 years, mean 
PaCO2 at presentation 63 
mmHg
Fixed CPAP (10 cmH2O), 
variable BiPAP (starting with 15 
and 5 cmH2O; titration of 
inspiratory pressure to achieve 
tidal volume >400 ml)
Proportion of patients with 
hospital mortality and requiring 
intubation, duration of 
noninvasive ventilation needed
Allocation concealment 
adequate; not blinded; no loss 
to follow up; analysis by 
intention to treat; Jadad scale 
score 3
[19] Worsening clinical signs 
(respiratory rate >40 or <10 
breaths/minute, reduced 
conscious level) associated 
with a falling arterial pH (less 
than at arrival and <7.2)
40 patients, mean APACHE II 
score not available, mean age 
75 years, mean PaCO2 at 
presentation 62 mmHg
Fixed CPAP (10 cmH2O), fixed 
BiPAP (15 and 5 cmH2O)
Proportion of patients with 
hospital mortality and requiring 
intubation, new onset 
myocardial infarction
Allocation concealment 
adequate; not blinded; no loss 
to follow up; analysis by 
intention to treat; Jadad scale 
score 3
APACHE, Acute Physiology and Chronic Health Evaluation; BiPAP = bi-level positive airway pressure; CPAP = continuous positive airway pressure; GCS, Glasgow Coma Scale; PCO2, partial 
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tidal volume of 400 ml), and three studies titrated the level of
both CPAP (5–20 cmH2O) and BiPAP (peak inspiratory pres-
sure range: 10–25 cmH2O). Four studies [9,17-19] recruited
patients who presented with hypercapnia (mean PaCO2 >45
mmHg). The mean age of the patients ranged from 61 to 77
years and the mean Acute Physiology and Chronic Health
Evaluation II scores ranged from 17 to 20 in the pooled stud-
ies. The Jadad scale scores of the studies ranged from 2 to 5
(mean 3). Allocation concealment was clearly adequate in four
studies but only one study used double blinding. The study
details are described in Table 1.
There was good overall consistency in most of the results,
without significant heterogeneity. Hospital mortality (RR 0.76,
95% CI 0.32–1.78; P = 0.52; I2 = 0%) and the risk for requir-
ing invasive ventilation (RR 0.80, 95% CI 0.33–1.94; P =
0.62;  I2  = 0%) were not significantly different between
patients treated with CPAP and those treated with BiPAP (Fig-
ures 2 and 3). Stratifying studies into use of BiPAP at variable
or fixed level of airway pressure did not change the results. The
relative risk ratios for hospital mortality and requiring invasive
ventilation between studies using BiPAP at a fixed level and
studies titrating the pressure were 3.38 (95% CI 0.30–37.60;
P = 0.32) and 1.26 (95% CI 0.15–10.94; P = 0.83), respec-
tively. Sensitivity analysis including studies that involved
patients with significant hypercapnia did not change the
results.
The duration of noninvasive ventilation needed until pulmonary
oedema resolved (WMD in hours = 3.65, 95% CI -12.12 to
+19.43; P = 0.65; I2 = 0%) and the length of hospital stay
(WMD in days = -0.04, 95% CI -2.57 to +2.48; P = 0.97; I2 =
0%) were not significantly different between the two groups
(Figures 4 and 5). Data on patients with new onset acute myo-
cardial infarction after initiation of CPAP or BiPAP were limited
and with some inconsistencies. Based on these limited data,
there was an insignificant trend toward an increase in new
onset myocardial infarction in patients treated with the BiPAP
(RR 2.10, 95% CI 0.91–4.84; P = 0.08; I2 = 25.3%; Figure
6). None of the studies included a cost-effectiveness analysis.
Discussion
Significance of the findings
The present meta-analysis indicates that BiPAP has no signif-
icant clinical advantage over CPAP in terms of reducing hos-
pital mortality, requirement for invasive ventilation, length of
Figure 4
Forest plot: effect of BiPAP and CPAP on duration of noninvasive ventilation needed to resolve pulmonary oedema Forest plot: effect of BiPAP and CPAP on duration of noninvasive ventilation needed to resolve pulmonary oedema. BiPAP, bi-level positive airway 
pressure; CI, confidence interval; CPAP, continuous positive airway pressure; WMD, weighted mean difference.
Figure 3
Forest plot: effect of BiPAP and CPAP on risk for requiring invasive ventilation Forest plot: effect of BiPAP and CPAP on risk for requiring invasive ventilation. BiPAP, bi-level positive airway pressure; CI, confidence interval; 
CPAP, continuous positive airway pressure; RR, relative risk.Critical Care    Vol 10 No 2    Ho and Wong 
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noninvasive ventilation needed until resolution of pulmonary
oedema, and hospital length of stay in patients with acute car-
diogenic pulmonary oedema. Based on the limited data availa-
ble, BiPAP was associated with a trend toward increased risk
for new onset acute myocardial infarction compared with
CPAP.
BiPAP can reduce work of breathing more than CPAP can in
patients with acute cardiogenic pulmonary oedema [6]. Titrat-
ing the level of airway pressure used during BiPAP to a tar-
geted tidal volume or to the patient's clinical needs may render
BiPAP more beneficial in patients with hypercapnic acute car-
diogenic pulmonary oedema because it reduces the work of
breathing more effectively than does CPAP while avoiding
unnecessary airway pressure that can cause an excessive
reduction in cardiac output [8]. However, we were unable to
demonstrate any significant clinical benefit of BiPAP over
CPAP, including in the subgroup of patients who received
titrated BiPAP support and in patients with significant hyper-
capnia. The reasons for the lack of benefit from BiPAP as com-
pared with CPAP in patients with acute cardiogenic
pulmonary oedema remain uncertain.
If we assume that the proportion of patients who may require
invasive ventilation or intubation in acute cardiogenic pulmo-
nary oedema is 10%, then the sample size of this meta-analy-
sis (n = 290) could only achieve a positive significant result if
the relative risk reduction for requiring intubation is more than
80% when BiPAP is compared with CPAP. On the other hand,
if the relative risk reduction for requiring intubation after use of
BiPAP is more modest (for example, 40%), then a sample size
of more than 600 patients would be needed to demonstrate
such a difference. Therefore, it is still possible that BiPAP is
superior to CPAP in acute cardiogenic pulmonary oedema but
that this meta-analysis was underpowered to detect such a
modest effect. A large randomized controlled study is needed
to confirm whether BiPAP is equivalent or superior to CPAP in
patients with acute cardiogenic pulmonary oedema.
The proportion of patients with new onset myocardial infarc-
tion was reported in four studies but there were some incon-
sistencies in the results [9,15,18,19]. Two studies reported an
insignificant increase in risk for new onset acute myocardial
infarction and two studies did not show such an effect [15,18].
Pooling the limited data together from these four studies
resulted in an insignificant trend toward an increase in risk for
new onset myocardial infarction. However, patients recruited
in these studies were, by nature, at high risk for developing
acute myocardial infarction, either before or during the early
phase of hospitalization. The small total number of patients
included in these four studies (n = 167) could have generated
a trend toward a false-positive result caused either by a small
imbalance in baseline characteristics of the patients or by just
a random effect. Nevertheless, use of excessive airway pres-
sure in CPAP or BiPAP has been demonstrated to reduce car-
diac output, especially when the left atrial filling pressure is
less than 12 mmHg [6,20]. When BiPAP was compared with
conventional medical therapy (without CPAP) in two moderate
size randomized controlled studies, there were no significant
differences in the incidence of new onset acute myocardial inf-
arction [8,15]. On the other hand, when BiPAP was compared
with high-dose intravenous isosorbide-dinitrate in acute car-
Figure 6
Forest Plot: effect if BiPAP and CPAP on risk of new onset myocardial infarction Forest Plot: effect if BiPAP and CPAP on risk of new onset myocardial infarction. BiPAP, bi-level positive airway pressure; CI, confidence interval; 
CPAP, continuous positive airway pressure; RR, relative risk.
Figure 5
Forest plot: effect of BiPAP and CPAP on length of hospital stay Forest plot: effect of BiPAP and CPAP on length of hospital stay. BiPAP, bi-level positive airway pressure; CI, confidence interval; CPAP, continuous 
positive airway pressure; WMD, weighted mean difference.Available online http://ccforum.com/content/10/2/R49
Page 7 of 8
(page number not for citation purposes)
diogenic pulmonary oedema, there was a significant increase
in myocardial infarction in patients treated with BiPAP [21].
Therefore, a small increase in risk for reducing cardiac output
and/or inducing myocardial ischaemia with BiPAP cannot
completely be excluded.
Cost-effectiveness analyses were not reported in any of the
pooled studies. A CPAP machine is, in general, cheaper than
a BiPAP machine [15]. Based on the lack of significant clinical
benefit identified in this meta-analysis, use of BiPAP instead of
CPAP is unlikely to be cost-effective in patients with acute car-
diogenic pulmonary oedema. Formal cost-effectiveness analy-
sis should be considered if a large randomized controlled
study comparing BiPAP and CPAP in patients with acute car-
diogenic pulmonary oedema is planned.
Limitations of the study
Meta-analyses are prone to bias. The quality of trials can affect
the direction and magnitude of treatment effect in such analy-
ses. Although most of the included studies had low patient
attrition and a Jadad scale score of 3 or higher, some degree
of double blinding was attempted only in one study by cover-
ing the control panel of the noninvasive ventilator [9]. The phy-
sicians who decided when to initiate invasive ventilation or to
cease noninvasive ventilation were not blinded to the assigned
mode of noninvasive ventilation in the other six studies, and
therefore bias might have affected the results. Future noninva-
sive ventilation studies should consider blinding the attending
physician to the mode of noninvasive ventilation used.
Publication bias can affect the direction and magnitude of the
results of a meta-analysis. The funnel plot showed that there
might be a small degree of publication bias, with the possibility
of missing two small studies (Fig. 7). Nevertheless, this small
potential bias was unlikely to change the significance and
direction of the results of the meta-analysis.
Conclusion
Based on the limited data available, BiPAP does not appear to
offer any significant clinical benefits over CPAP in patients
with acute cardiogenic pulmonary oedema. Until a large rand-
omized controlled trial can demonstrate that BiPAP is associ-
ated with significant clinical benefit or is more cost-effective
than CPAP in patients with acute cardiogenic pulmonary
oedema, the choice of modality will depend mainly on the
equipment available.
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